Literature DB >> 21098396

Immunoglobulin light chains activate nuclear factor-κB in renal epithelial cells through a Src-dependent mechanism.

Wei-Zhong Ying1, Pei-Xuan Wang, Kristal J Aaron, Kolitha Basnayake, Paul W Sanders.   

Abstract

One of the major attendant complications of multiple myeloma is renal injury, which contributes significantly to morbidity and mortality in this disease. Monoclonal immunoglobulin free light chains (FLCs) are usually directly involved, and tubulointerstitial renal injury and fibrosis are prominent histologic features observed in myeloma. The present study examined the role of monoclonal FLCs in altering the nuclear factor κ light chain enhancer of activated B cells (NF-κB) activity of renal epithelial cells. Human proximal tubule epithelial cells exposed to 3 different human monoclonal FLCs demonstrated Src kinase-dependent activation of the NF-κB pathway, which increased production of monocyte chemoattractant protein-1 (MCP-1). Tyrosine phosphorylation of inhibitor of κB kinases (IKKs) IKKα and IKKβ and a concomitant increase in inhibitor of κB (IκB) kinase activity in cell lysates were observed. Time-dependent, Src kinase-dependent increases in serine and tyrosine phosphorylation of IκBα and NF-κB activity were also demonstrated. Proteasome inhibition partially blocked FLC-induced MCP-1 production. These findings fit into a paradigm characterized by FLC-induced redox-signaling events that activated the canonical and atypical (IKK-independent) NF-κB pathways to promote a proinflammatory, profibrotic renal environment.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21098396      PMCID: PMC3056473          DOI: 10.1182/blood-2010-08-302505

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  43 in total

1.  Intracellular reactive oxygen species activate Src tyrosine kinase during cell adhesion and anchorage-dependent cell growth.

Authors:  Elisa Giannoni; Francesca Buricchi; Giovanni Raugei; Giampietro Ramponi; Paola Chiarugi
Journal:  Mol Cell Biol       Date:  2005-08       Impact factor: 4.272

Review 2.  Integrating cell-signalling pathways with NF-kappaB and IKK function.

Authors:  Neil D Perkins
Journal:  Nat Rev Mol Cell Biol       Date:  2007-01       Impact factor: 94.444

3.  Potential protective action of pituitary adenylate cyclase-activating polypeptide (PACAP38) on in vitro and in vivo models of myeloma kidney injury.

Authors:  Akira Arimura; Min Li; Vecihi Batuman
Journal:  Blood       Date:  2005-10-04       Impact factor: 22.113

4.  The signal transduction pathway of CD23 (Fc epsilon RIIb) targets I kappa B kinase.

Authors:  R M Ten; M J McKinstry; S A Trushin; S Asin; C V Paya
Journal:  J Immunol       Date:  1999-10-01       Impact factor: 5.422

5.  Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study.

Authors:  Asher A Chanan-Khan; Jonathan L Kaufman; Jayesh Mehta; Paul G Richardson; Kena C Miller; Sagar Lonial; Nikhil C Munshi; Robert Schlossman; Joseph Tariman; Seema Singhal
Journal:  Blood       Date:  2006-11-30       Impact factor: 22.113

6.  EGF receptor activity modulates apoptosis induced by inhibition of the proteasome of vascular smooth muscle cells.

Authors:  Wei-Zhong Ying; Huang-Ge Zhang; Paul W Sanders
Journal:  J Am Soc Nephrol       Date:  2006-12-06       Impact factor: 10.121

7.  Bortezomib in recurrent and/or refractory multiple myeloma. Initial clinical experience in patients with impared renal function.

Authors:  Sundar Jagannath; Bart Barlogie; James R Berenson; Seema Singhal; Raymond Alexanian; Gordan Srkalovic; Robert Z Orlowski; Paul G Richardson; Jessica Anderson; Darrell Nix; Dixie L Esseltine; Kenneth C Anderson
Journal:  Cancer       Date:  2005-03-15       Impact factor: 6.860

8.  Light chains are a ligand for megalin.

Authors:  R Bryan S Klassen; Patricia L Allen; Vecihi Batuman; Kimberly Crenshaw; Timothy G Hammond
Journal:  J Appl Physiol (1985)       Date:  2004-07-30

9.  Immunoglobulin light chains generate hydrogen peroxide.

Authors:  Pei-Xuan Wang; Paul W Sanders
Journal:  J Am Soc Nephrol       Date:  2007-03-14       Impact factor: 10.121

10.  Efficacy and mechanism of action of the proteasome inhibitor PS-341 in T-cell lymphomas and HTLV-I associated adult T-cell leukemia/lymphoma.

Authors:  Rihab Nasr; Marwan E El-Sabban; José-Antonio Karam; Ghassan Dbaibo; Youmna Kfoury; Bertrand Arnulf; Yves Lepelletier; Françoise Bex; Hugues de Thé; Olivier Hermine; Ali Bazarbachi
Journal:  Oncogene       Date:  2005-01-13       Impact factor: 9.867

View more
  23 in total

1.  Pivotal role of apoptosis signal-regulating kinase 1 in monoclonal free light chain-mediated apoptosis.

Authors:  Wei-Zhong Ying; Pei-Xuan Wang; Paul W Sanders
Journal:  Am J Pathol       Date:  2011-11-10       Impact factor: 4.307

Review 2.  The pathogenesis and diagnosis of acute kidney injury in multiple myeloma.

Authors:  Colin A Hutchison; Vecihi Batuman; Judith Behrens; Frank Bridoux; Christophe Sirac; Angela Dispenzieri; Guillermo A Herrera; Helen Lachmann; Paul W Sanders
Journal:  Nat Rev Nephrol       Date:  2011-11-01       Impact factor: 28.314

Review 3.  Myeloma light chain cast nephropathy, a review.

Authors:  Insara Jaffer Sathick; Maria Eleni Drosou; Nelson Leung
Journal:  J Nephrol       Date:  2018-05-05       Impact factor: 3.902

4.  Immunoglobulin light chains generate proinflammatory and profibrotic kidney injury.

Authors:  Wei-Zhong Ying; Xingsheng Li; Sunil Rangarajan; Wenguang Feng; Lisa M Curtis; Paul W Sanders
Journal:  J Clin Invest       Date:  2019-06-17       Impact factor: 14.808

Review 5.  Novel approaches for reducing free light chains in patients with myeloma kidney.

Authors:  Colin A Hutchison; Joan Bladé; Paul Cockwell; Mark Cook; Mark Drayson; Jean-Paul Fermand; Efstathios Kastritis; Robert Kyle; Nelson Leung; Sonia Pasquali; Christopher Winearls
Journal:  Nat Rev Nephrol       Date:  2012-02-21       Impact factor: 28.314

6.  Serum free light chains and the risk of ESRD and death in CKD.

Authors:  Richard Haynes; Colin A Hutchison; Jonathan Emberson; Tanaji Dasgupta; David C Wheeler; John N Townend; Martin J Landray; Paul Cockwell
Journal:  Clin J Am Soc Nephrol       Date:  2011-10-27       Impact factor: 8.237

7.  A novel inhibitor of STAT3 homodimerization selectively suppresses STAT3 activity and malignant transformation.

Authors:  Xiaolei Zhang; Ying Sun; Roberta Pireddu; Hua Yang; Murali K Urlam; Harshani R Lawrence; Wayne C Guida; Nicholas J Lawrence; Saïd M Sebti
Journal:  Cancer Res       Date:  2013-01-15       Impact factor: 12.701

8.  Paraprotein-Related Kidney Disease: Evaluation and Treatment of Myeloma Cast Nephropathy.

Authors:  Kevin W Finkel; Eric P Cohen; Anushree Shirali; Ala Abudayyeh
Journal:  Clin J Am Soc Nephrol       Date:  2016-08-15       Impact factor: 8.237

9.  Impaired Lysosomal Function Underlies Monoclonal Light Chain-Associated Renal Fanconi Syndrome.

Authors:  Alessandro Luciani; Christophe Sirac; Sara Terryn; Vincent Javaugue; Jenny Ann Prange; Sébastien Bender; Amélie Bonaud; Michel Cogné; Pierre Aucouturier; Pierre Ronco; Frank Bridoux; Olivier Devuyst
Journal:  J Am Soc Nephrol       Date:  2015-11-27       Impact factor: 10.121

10.  Prooxidant-induced c-Src/nuclear factor kappa B-coupled signalling in sensory ganglia mediates cutaneous hyperalgesia.

Authors:  O J Igwe
Journal:  Eur J Pain       Date:  2012-12-27       Impact factor: 3.931

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.